UK's Poor Uptake Of New Drugs May Be Hitting Clinical Trial Investment
Executive Summary
The pharmaceutical industry wants the UK to improve its uptake of innovative medicines in order to spur investment in clinical trials under the government's life sciences sector deal. One industry representative says companies are already questioning the ethics of conducting trials in a country where their drug might not be commercialized.
You may also be interested in...
RWE and Clinical Trials To Take Center Stage In UK Sector Deal Prospects
Some of the loudest messages from UK government's Life Science Sector Deal was the importance of using real world evidence - and the uniqueness the British health ecosystem can offer to trail blazing innovation.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.